Drug Trial Radar · NCT06780449
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Feb 10, 2025
Primary completion
Aug 28, 2028
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.
Conditions
- Obesity
Interventions
CagrilintideDrug
Participants will receive cagrilintide subcutaneously.
SemaglutideDrug
Participants will receive semaglutide subcutaneously.
Placebo cagrilintideDrug
Participants will receive placebo matched to cagrilintide subcutaneously.
Placebo semaglutideDrug
Participants will receive placebo matched to semaglutide subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in body weightTime frame: From baseline (week 0) to week 104
Locations
36 sites in 6 countries. Site status is shown where the registry gives one.
Valley Clinical Trials
Covina, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Yale University School Of Medicine
New Haven, Connecticut
East West Medical Research Institute_Honolulu
Honolulu, Hawaii
L-MARC Research Center
Louisville, Kentucky
StudyMetrix Research LLC
City of Saint Peters, Missouri
Spartanburg Medical Research
Spartanburg, South Carolina
Holston Medical Group_Bristol
Bristol, Tennessee
North Texas Endocrine Center
Dallas, Texas
Washington Cntr Weight Mgmt
Arlington, Virginia
Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie
Brussels, Belgium
UZA - UZ Antwerpen - Department of Endocrinology
Edegem, Belgium
UZ Leuven - Endocrinology
Leuven, Belgium
CHU Helora - Hôpital de Mons - Site Constantinople
Mons, Belgium
Alpha Recherche Clinique - Lebourgneuf
Québec, Canada
Dr. M.B. Jones Inc
Victoria, British Columbia, Canada
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, Canada
Aarhus Universitetshospital, Steno Diabetes Center Aarhus
Aarhus, Denmark
Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden
Esbjerg, Denmark
Gentofte Hospital - Center for Klinisk Metabolisk Forskning
Hellerup, Denmark
Hvidovre Hospital Endokrinologisk forsknings afsnit 159
Hvidovre, Denmark
Sjællands Universitetshospital, Køge - Medicinsk Afdeling
Køge, Denmark
APDP - Associação Protectora dos Diabéticos de Portugal
Lisbon, Portugal
CUF Descobertas
Lisbon, Portugal
Hospital Cuf Descobertas S.A.
Lisbon, Portugal
Unidade Local de Saude de Sao Joao E.P.E
Porto, Portugal
Hospital Luz Arrabida, S.A.
Vila Nova de Gaia, Portugal
ULS De Matosinhos E.P.E.- Hospital Pedro Hispano
Senhora Da Hora, Matosinhos, Matosinhos, Portugal
Southmead Hospital
Bristol, United Kingdom
Addenbrooke's Hospital_Cambridge
Cambridge, United Kingdom
University Hospital Coventry - WISDEM Centre
Coventry, United Kingdom
Aintree University Hospital
Liverpool, United Kingdom
Royal London Hospital - Blizard Institute
London, United Kingdom
Joint Clinical Research Facility - Swansea
Swansea, United Kingdom
Musgrove Park Hospital
Taunton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.